Heidelberg Pharma AG announced new clinical data on its lead Antibody Drug Conjugate (ADC) candidate, HDP-101, at the International Myeloma Society Annual Meeting. The Phase I/IIa trial evaluates HDP-101 in patients with relapsed or refractory multiple myeloma.
HDP-101 is an Anti-BCMA antibody-Amanitin conjugate designed to target and kill multiple myeloma cells. The Phase I portion of the trial is a dose escalation study to determine the optimal and safe dose of HDP-101 for further clinical development.
Promising Early Results
Professor Marc-Steffen Raab, Head of the Myeloma Center at the University Hospital Heidelberg, presented clinical findings from five patient cohorts. Previous data from cohort five demonstrated biological activity in three out of five patients, with one patient achieving a partial remission. The trial is currently treating patients in its sixth cohort, and further data will be presented at upcoming scientific conferences.
About the HDP-101 Trial
The ongoing open-label, multicenter Phase I/IIa trial is evaluating HDP-101 in patients with multiple myeloma who have relapsed or are refractory to previous treatments. HDP-101 utilizes Heidelberg Pharma’s Amanitin-based ADC technology to deliver a potent toxin specifically to BCMA-expressing tumor cells.
Future Plans
Heidelberg Pharma will host an R&D Webinar on October 15, 2024, for investors, analysts, and media to discuss the clinical trial results and future development plans for HDP-101.
